ResMed Inc. (NASDAQ:RMD) Chairman and Chief Executive Officer Michael J. Farrell executed a structured sale of company stock on June 8, 2026, divesting 4,991 shares of common stock. The transaction, valued at $968,064, was executed at prices ranging from $192.605 to $194.715 per share, resulting in a weighted average sale price of $193.962. The sale was carried out under a Rule 10b5-1 trading plan that Farrell established on October 31, 2024.
Concurrently with the sale, Farrell acquired 4,991 shares of ResMed common stock by exercising options at a strike price of $146.34 per share. This option exercise totaled $730,382 and derived from a grant issued on November 11, 2020, which carries an expiration date of November 21, 2026.
Following these transactions, Farrell's direct ownership stands at 466,256 shares. This figure includes 32,671 shares acquired on April 30, 2026, through the ResMed Employee Stock Purchase Plan. Indirect holdings through the Lisette and Michael Farrell Family Trust amount to 2,090 shares. Post-exercise, Farrell retains 24,957 unexercised derivative options.
ResMed's stock currently trades at $196.48, placing the medical device manufacturer at a market capitalization of $28.4 billion. The company recently reported fiscal third-quarter earnings for 2026, presenting a mixed financial picture. Earnings per share reached $2.86, surpassing the forecasted $2.81 by 1.78%. However, revenue came in at $1.43 billion, slightly missing the $1.42 billion estimate by 1.41%.
Strategically, ResMed announced the acquisition of Noctrix Health for $340 million, with a closing date set for June 1, 2026. Analyst responses to these developments have diverged. RBC Capital raised its price target to $321 from $314, highlighting double-digit revenue and earnings growth that exceeded expectations. Conversely, Wolfe Research lowered its price target to $180 from $230, maintaining an Underperform rating and forecasting organic growth between 6% and 7%. Needham reiterated a Hold rating following the acquisition announcement.
According to InvestingPro analysis, ResMed appears undervalued at current levels and has increased its dividend for 14 consecutive years. Investors can access exclusive insights including Fair Value estimates and over 10 additional ProTips for RMD. The stock showed a real-time value of $196.80, reflecting a +3.66 (+1.90%) change.